EGFR and prostate cancer: In the 1990s, leflunomide was evaluated as an epidermal growth factor receptor (EGFR) inhibitor with potential anticancer applications.103,104 Recent studies have highlighted its potential in treating breast and prostate cancer.105,106 In addition, Yamaguchi and colleagues proposed that leflunomide-mediated pyrimidine synthesis could be a therapeutic target for mitigating the metastatic progression of CRC.